AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35483010 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by chemoradiotherapy (INCT‐CRT)
Number of subjects: 324
Study 35483010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy followed by consolidation chemotherapy (CRT‐CNCT)
Number of subjects: 324
Study 34913976 — intervention group
Group type: EXPERIMENTAL
Intervention: Values affirmation writing exercise
Number of subjects: 960
Study 34913976 — intervention group
Group type: COMPARATOR
Intervention: Control writing exercise
Number of subjects: 960
Study 32649011 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective Caesarean section at early-term (38+3 weeks)
Number of subjects: 574
Study 32649011 — intervention group
Group type: COMPARATOR
Intervention: Elective Caesarean section at full-term (39+3 weeks)
Number of subjects: 574
Study 32773296 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic approach
Number of subjects: 344
Study 32773296 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal laparoscopic approach
Number of subjects: 344
Study 32354280 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone treatment
Number of subjects: 6632
Study 35684021 — intervention group
Group type: EXPERIMENTAL
Intervention: RiaGev (Nicotinamide and D-Ribose) 1520 mg twice daily for 7 days
Number of subjects: 0
Study 33754416 — intervention group
Group type: COMPARATOR
Intervention: Small number of reward points for dementia prevention activities
Number of subjects: 1500
Study 33754416 — intervention group
Group type: EXPERIMENTAL
Intervention: Time credits for support activities
Number of subjects: 1500
Study 33754416 — intervention group
Group type: COMPARATOR
Intervention: Small cash reward for support activities
Number of subjects: 1500
Study 33754416 — intervention group
Group type: COMPARATOR
Intervention: No incentives for support activities
Number of subjects: 1500
Study 32120378 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1519
Study 32120378 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1519
Study 36123654 — intervention group
Group type: EXPERIMENTAL
Intervention: Confederate group
Number of subjects: 63
Study 36123654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 36123654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 33620439 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥50% of the target β-blocker dose
Number of subjects: 97575
Study 33620439 — intervention group
Group type: COMPARATOR
Intervention: <50% of the target β-blocker dose
Number of subjects: 97575
Study 32331073 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Number of subjects: 60
Study 32331073 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60
Study 32331073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36440867 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration bee with cold
Number of subjects: 120
Study 36440867 — intervention group
Group type: EXPERIMENTAL
Intervention: Whistling (concentrate on breathing)
Number of subjects: 120
Study 36440867 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 33515432 — intervention group
Group type: EXPERIMENTAL
Intervention: Untargeted metabolomics using LC-MS/MS on newborn screening dried blood spot (DBS) samples
Number of subjects: 37
Study 33515432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age, age at sampling, and month of birth
Number of subjects: 37
Study 32345747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide and lanthanum carbonate
Number of subjects: 122
Study 32345747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ADC (apparent diffusion coefficient)
Number of subjects: 122
Study 32345747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ADC (after adjustment for albuminuria)
Number of subjects: 122
Study 32345747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline R2* (relaxation rate)
Number of subjects: 122
Study 32345747 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up functional MRI (87 participants)
Number of subjects: 122
Study 34801508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based training (n=17)
Number of subjects: 33
Study 34801508 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (n=16)
Number of subjects: 33
Study 32094049 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin implant
Number of subjects: 288
Study 32094049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implant)
Number of subjects: 288
Study 34410393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial information on carotid ultrasonographic determination of vascular age
Number of subjects: 3532
Study 34410393 — intervention group
Group type: COMPARATOR
Intervention: No pictorial information (Control)
Number of subjects: 3532
Study 32326948 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual VR
Number of subjects: 289
Study 32326948 — intervention group
Group type: COMPARATOR
Intervention: Individual TP
Number of subjects: 289
Study 34280377 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 1212487
Study 33628801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7% wt. monopotassium‐monohydrogen oxalate (Mp‐Mh oxalate)
Number of subjects: 42
Study 33628801 — intervention group
Group type: COMPARATOR
Intervention: RMGI XT VAR
Number of subjects: 42
Study 33628801 — intervention group
Group type: COMPARATOR
Intervention: LIQ SiO2
Number of subjects: 42
Study 33932526 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 53
Study 33932526 — intervention group
Group type: COMPARATOR
Intervention: Stretching (active control)
Number of subjects: 53
Study 35810479 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (sham acupuncture)
Number of subjects: 90
Study 35810479 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 33239152 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled control medication (ICM)
Number of subjects: 442
Study 33239152 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta-agonists (SABA)
Number of subjects: 442
Study 33239152 — intervention group
Group type: EXPERIMENTAL
Intervention: SABA
Number of subjects: 442
Study 35185010 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 613
Study 35185010 — intervention group
Group type: COMPARATOR
Intervention: Open microdiscectomy
Number of subjects: 613
Study 33692404 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Nutrition intervention
Number of subjects: 0
Study 33692404 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH/Malaria intervention
Number of subjects: 0
Study 33692404 — intervention group
Group type: COMPARATOR
Intervention: Test-and-treat intervention
Number of subjects: 0
Study 33627253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum MBL (≤100 μg/L)
Number of subjects: 7305
Study 33627253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MBL expression genotype
Number of subjects: 7305
Study 32176862 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-exercise (EEex goal of 17.5 kcal/kg/wk)
Number of subjects: 60
Study 32176862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-exercise (EEex goal of 35 kcal/kg/wk)
Number of subjects: 60
Study 32176862 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 60
Study 34000251 — intervention group
Group type: EXPERIMENTAL
Intervention: Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg
Number of subjects: 1864
Study 32500130 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 320
Study 32500130 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 320
Study 32500130 — intervention group
Group type: COMPARATOR
Intervention: Back Pain Education (Control)
Number of subjects: 320
Study 34856577 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 5759
Study 34856577 — intervention group
Group type: COMPARATOR
Intervention: Induction of labor
Number of subjects: 5759
Study 32690640 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu-pGSN single-dose at 6 mg/kg
Number of subjects: 33
Study 32690640 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu-pGSN multidose at 6, 12, or 24 mg/kg for 3 consecutive days
Number of subjects: 33
Study 32690640 — intervention group
Group type: COMPARATOR
Intervention: Placebo single-dose
Number of subjects: 33
Study 32690640 — intervention group
Group type: COMPARATOR
Intervention: Placebo multidose
Number of subjects: 33
Study 35882692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) based HIPEC
Number of subjects: 137
Study 35882692 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin based HIPEC
Number of subjects: 137
Study 33146720 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix‐M–adjuvanted qNIV
Number of subjects: 1375
Study 33146720 — intervention group
Group type: COMPARATOR
Intervention: IIV3‐HD
Number of subjects: 1375
Study 33146720 — intervention group
Group type: COMPARATOR
Intervention: RIV4
Number of subjects: 1375
Study 34611470 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 608
Study 34611470 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 608
Study 35839439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination cognitive behavioral therapy and medication management algorithm
Number of subjects: 156
Study 35839439 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care (psychotherapy and medication management)
Number of subjects: 156
Study 34948650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D)
Number of subjects: 1864
Study 35778701 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) with 6 cm H2O PEEP
Number of subjects: 42
Study 35778701 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with 6 cm H2O PEEP and no RM
Number of subjects: 42
Study 33688711 — intervention group
Group type: EXPERIMENTAL
Intervention: Shadent software
Number of subjects: 250
Study 33688711 — intervention group
Group type: COMPARATOR
Intervention: Visual method
Number of subjects: 250
Study 33688711 — intervention group
Group type: COMPARATOR
Intervention: Spectrophotometer
Number of subjects: 250
Study 32546139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention + real-time fMRI neurofeedback targeting ventral striatum
Number of subjects: 88
Study 32546139 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-based relapse prevention + real-time fMRI neurofeedback targeting auditory cortex (control)
Number of subjects: 88
Study 32546139 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback targeting ventral striatum
Number of subjects: 88
Study 32546139 — intervention group
Group type: COMPARATOR
Intervention: Real-time fMRI neurofeedback targeting auditory cortex (control)
Number of subjects: 88
Study 34510174 — intervention group
Group type: EXPERIMENTAL
Intervention: High-spice diet (HSD) 6.6 g/d/2100 kcal
Number of subjects: 71
Study 34510174 — intervention group
Group type: COMPARATOR
Intervention: Moderate-spice diet (MSD) 3.3 g/d/2100 kcal
Number of subjects: 71
Study 34510174 — intervention group
Group type: COMPARATOR
Intervention: Low-spice diet (LSD) 0.5 g/d/2100 kcal
Number of subjects: 71
Study 33296878 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel automatic algorithm for diagnosing sleep apnea from nasal airflow (AF) and pulse oximetry (SpO2) signals
Number of subjects: 988
Study 33296878 — intervention group
Group type: COMPARATOR
Intervention: Scored SHHS data
Number of subjects: 988
Study 36075583 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (RT) using digital material or storytelling for 4 weeks
Number of subjects: 0
Study 36075583 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (RT)
Number of subjects: 0
Study 34242960 — intervention group
Group type: EXPERIMENTAL
Intervention: 2019 survey participants
Number of subjects: 1588
Study 35104297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings on sugary drinks (warnings about type 2 diabetes and heart damage)
Number of subjects: 325
Study 35104297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings on sugary drinks
Number of subjects: 325
Study 35104297 — intervention group
Group type: COMPARATOR
Intervention: Control arm (barcode label)
Number of subjects: 325
Study 34168337 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization null models
Number of subjects: 0
Study 34168337 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32347687 — intervention group
Group type: EXPERIMENTAL
Intervention: mIOL
Number of subjects: 100
Study 32347687 — intervention group
Group type: COMPARATOR
Intervention: IOL
Number of subjects: 100
Study 34724559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 731
Study 34724559 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 731
Study 34724559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-maximum lysis
Number of subjects: 731
Study 34724559 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal maximum lysis
Number of subjects: 731
Study 32385554 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine solution (CHG)
Number of subjects: 50
Study 32385554 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% benzoyl peroxide soap (BPO)
Number of subjects: 50
Study 34114501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable bone hemostatic agent (BBHA)
Number of subjects: 62
Study 34114501 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 34246129 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) exercises
Number of subjects: 53
Study 34015041 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day levofloxacin treatment
Number of subjects: 241
Study 34015041 — intervention group
Group type: COMPARATOR
Intervention: CRP-guided levofloxacin treatment
Number of subjects: 241
Study 33074327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 700 mg monthly for 6 months
Number of subjects: 180
Study 33074327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 35380078 — intervention group
Group type: COMPARATOR
Intervention: Placebo-siponimod
Number of subjects: 0
Study 32872052 — intervention group
Group type: EXPERIMENTAL
Intervention: XCARE technology spiral CT scan
Number of subjects: 560
Study 32872052 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-dose spiral CT scan
Number of subjects: 560
Study 35758442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual trigger using gonadotropin releasing hormone agonist with human chorionic gonadotropin (hCG)
Number of subjects: 90
Study 35758442 — intervention group
Group type: COMPARATOR
Intervention: hCG alone
Number of subjects: 90
Study 35758442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Dual trigger and hCG alone)
Number of subjects: 90
Study 34060901 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 552
Study 34060901 — intervention group
Group type: COMPARATOR
Intervention: other regimens
Number of subjects: 552
Study 35854370 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent policy package implemented for 6 months in preschools randomized to intervention
Number of subjects: 4000
Study 35854370 — intervention group
Group type: COMPARATOR
Intervention: Control group (preschools not receiving the intervention)
Number of subjects: 4000
Study 35854370 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent policy package
Number of subjects: 4000
Study 35854370 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4000
Study 33411801 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible parametric model with frailty (df = 2)
Number of subjects: 596
Study 32833767 — intervention group
Group type: COMPARATOR
Intervention: Standard Time to Surgery (TTS) 4-6 weeks
Number of subjects: 249
Study 32833767 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Time to Surgery (TTS) 10-12 weeks
Number of subjects: 249
Study 37150783 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat revascularization (RR) within 5 years
Number of subjects: 1800
Study 37150783 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat revascularization (RR) within 5 years in the PCI arm
Number of subjects: 1800
Study 37150783 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat revascularization (RR) within 5 years in the CABG arm
Number of subjects: 1800
Study 37150783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring RR who underwent PCI as initial revascularization
Number of subjects: 1800
Study 34230562 — intervention group
Group type: EXPERIMENTAL
Intervention: ABUS
Number of subjects: 1947
Study 34230562 — intervention group
Group type: EXPERIMENTAL
Intervention: HHUS
Number of subjects: 1947
Study 33137120 — intervention group
Group type: EXPERIMENTAL
Intervention: Single SNP-based alternative method for causal inference
Number of subjects: 0
Study 33137120 — intervention group
Group type: COMPARATOR
Intervention: Steiger’s method
Number of subjects: 0
Study 33137120 — intervention group
Group type: COMPARATOR
Intervention: Bi-directional MR
Number of subjects: 0
Study 34348576 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) as an adjunct to anti-seizure medications (ASMs)
Number of subjects: 0
Study 34348576 — intervention group
Group type: COMPARATOR
Intervention: Anti-seizure medications (ASMs) only
Number of subjects: 0
Study 36454580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib in combination with trastuzumab and capecitabine
Number of subjects: 612
Study 36454580 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with trastuzumab and capecitabine
Number of subjects: 612
Study 33373672 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care with polyethylene bags
Number of subjects: 423
Study 33373672 — intervention group
Group type: COMPARATOR
Intervention: Skin-to-skin care alone
Number of subjects: 423
Study 32381013 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit + implementation facilitation
Number of subjects: 0
Study 32381013 — intervention group
Group type: COMPARATOR
Intervention: Toolkit + implementation as usual
Number of subjects: 0
Study 34779542 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 LCPUFA
Number of subjects: 12
Study 34779542 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oils (placebo)
Number of subjects: 12
Study 33829720 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% miswak mouthwash
Number of subjects: 60
Study 33829720 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 60
Study 34515160 — intervention group
Group type: EXPERIMENTAL
Intervention: RPM-APD
Number of subjects: 57
Study 34515160 — intervention group
Group type: COMPARATOR
Intervention: T-APD
Number of subjects: 57
Study 34988963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric block (Group I)
Number of subjects: 60
Study 34988963 — intervention group
Group type: COMPARATOR
Intervention: Sacral epidural block (Group S)
Number of subjects: 60
Study 34988963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group S)
Number of subjects: 60
Study 36116461 — intervention group
Group type: EXPERIMENTAL
Intervention: V116-1 (2 μg per pneumococcal polysaccharide [PnP] per 0·5 mL)
Number of subjects: 600
Study 36116461 — intervention group
Group type: EXPERIMENTAL
Intervention: V116-2 (4 μg per PnP per 1·0 mL)
Number of subjects: 600
Study 36116461 — intervention group
Group type: COMPARATOR
Intervention: PPSV23 (25 μg per PnP per 0·5 mL)
Number of subjects: 600
Study 36116461 — intervention group
Group type: EXPERIMENTAL
Intervention: V116 (4 μg per PnP per 1·0 mL)
Number of subjects: 600
Study 36116461 — intervention group
Group type: EXPERIMENTAL
Intervention: V116-1
Number of subjects: 600
Study 36116461 — intervention group
Group type: EXPERIMENTAL
Intervention: V116-2
Number of subjects: 600
Study 36116461 — intervention group
Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 600
Study 36116461 — intervention group
Group type: EXPERIMENTAL
Intervention: V116
Number of subjects: 600
Study 34283711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Scholar (internet-based insomnia intervention)
Number of subjects: 38
Study 32046752 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical indices for diagnosing PCOS (experimental group 1)
Number of subjects: 276
Study 32046752 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic indices for diagnosing PCOS (experimental group 2)
Number of subjects: 276
Study 32046752 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no PCOS)
Number of subjects: 276
Study 34958620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin plus misoprostol (400 µg sublingual)
Number of subjects: 1036
Study 34958620 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin plus placebo
Number of subjects: 1036
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Tongtian Oral Liquid
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Zhengtian Pills
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Toutongning Capsules
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Yangxue Qingnao Granules
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Tianshu Capsules
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Xuefu Zhuyu Capsules
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Danzhen Toutong Capsules
Number of subjects: 52
Study 33350222 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Chuanxiong Qingnao Granules
Number of subjects: 52